CDA | Evidence Driven
CDA | Evidence Driven

Xtandi for metastatic Castration Resistant Prostate Cancer - Details

Details

Files
Generic Name:
Enzalutamide
Project Status:
Complete
Therapeutic Area:
Metastatic Castration Resistant Prostate Cancer
Manufacturer:
Astellas Pharma Canada Inc.
Brand Name:
Xtandi
Project Line:
Reimbursement Review
Project Number:
PC0023-000
Performance Metric:
N/A — Predated performance metrics
Strength:
40 mg tablet
Tumour Type:
Genitourinary
Indications:
Metastatic Castration Resistant Prostate Cancer
Funding Request:
For the treatment of patients with metastatic castration-resistant prostate cancer, who have previously received docetaxel therapy
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Astellas Pharma Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Enzalutamide (Xtandi) for mCRPC - pERC Final Recommendation Final Recommendation July 23, 2013 View PDF
Enzalutamide (Xtandi) for mCRPC - Final Clinical Guidance Report Guidance Reports July 23, 2013 View PDF
Enzalutamide (Xtandi) for mCRPC - Final Economic Guidance Report Guidance Reports View PDF
Enzalutamide (Xtandi) for mCRPC - pERC Initial Recommendation Initial Recommendation July 5, 2013 View PDF
Enzalutamide (Xtandi) for mCRPC - PAG Feedback on Initial Recommendation Feedback July 23, 2013 View PDF
Enzalutamide (Xtandi) for mCRPC - Manufacturer (Astellas) Feedback on Initial Recommendation Feedback July 23, 2013 View PDF
Enzalutamide (Xtandi) for mCRPC - Patient Advocacy Group (PCC) COI Declarations Feedback July 23, 2013 View PDF
Enzalutamide (Xtandi) for mCRPC - Patient Advocacy Group (CCSN) COI Declarations Feedback July 23, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : August 8, 2013